Vaccine Adjuvants
AssigneeSeqirus Inc.
InventorsDouglas G. Widman, Palaniappan Ramanathan
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to RNAs and other polynucleotides encoding an antigen, which can be used in vaccine compositions. In some examples, the RNA or polynucleotide also encodes an adjuvant, such as cathelicidin or a fragment thereof. The present disclosure also relates to use of the RNAs, polynucleotides or compositions in methods of inducing an immune response in a subject.
Claims74
A self-replicating RNA comprising a first nucleotide sequence encoding an antigen operably linked to a regulatory element, and a second nucleotide sequence encoding an adjuvant operably linked to a regulatory element, wherein the adjuvant is cathelicidin or a fragment thereof.
An immunogenic composition comprising:
- a) a self-replicating RNA comprising a first nucleotide sequence encoding an antigen operably linked to a regulatory element;
- and
- b) a cathelicidin polypeptide or a fragment thereof.
A polynucleotide comprising:
- a) a first nucleotide sequence encoding an antigen operably linked to a regulatory element;
- and
- b) a second nucleotide sequence encoding an adjuvant operably linked to a regulatory element selected from the group consisting of a SG promoter and an internal ribosome entry site (IRES),
- wherein the adjuvant is cathelicidin or a fragment thereof.
A conventional mRNA (cRNA) comprising:
- a) a first nucleotide sequence encoding an antigen operably linked to a regulatory element;
- and
- b) a second nucleotide sequence encoding an adjuvant operably linked to a regulatory element selected from the group consisting of a SG promoter and an internal ribosome entry site (IRES),
- wherein the adjuvant is a cathelicidin or a fragment thereof.
Dependencies are inferred from the claim text.